Biopharma | January 11, 2026
Prokaryotics and Basilea team up to tackle deadly fungal infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Subscribe To Our Newsletter & Stay Updated
